Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

ADCs and TKIs Plus Immunotherapy Signal the Future of Urothelial Carcinoma and RCC

July 12th 2022

Benjamin Garmezy, MD, discussed the positive trajectory of antibody-drug conjugates and immunotherapy in urothelial carcinoma, highlighting the importance of considering individual patient eligibility for treatments like first-line chemotherapy.

Dr. Barata on the Challenges of Treating Advanced Urothelial Carcinoma

July 11th 2022

Pedro C. Barata, MD, MSc, discusses challenges associated with treating advanced urothelial carcinoma.

FDA Grants Fast Track Designation to Belzupacap Sarotalocan for Non–Muscle Invasive Bladder Cancer

July 7th 2022

The FDA has granted a fast track designation to belzupacap sarotalocan for the treatment of patients with non–muscle invasive bladder cancer, representing the first virus-like drug conjugate candidate therapy from Aura Biosciences, Inc., the drug developer.

Tislelizumab Plus Nab-Paclitaxel Elicits Responses in High-Risk, Non–Muscle Invasive Bladder Cancer

July 5th 2022

The addition of tislelizumab to nab-paclitaxel demonstrated efficacy and safety in patients with high-risk non–muscle invasive bladder cancer.

Enfortumab Vedotin Maintains Long-Term OS Benefit in Advanced Urothelial Carcinoma

July 3rd 2022

Enfortumab vedotin extended overall survival by 3.97 months compared with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma.

Disitamab Vedotin Shows Efficacy in HER2-Negative Metastatic Urothelial Carcinoma

June 30th 2022

Disitamab vedotin demonstrated promising efficacy with a tolerable safety profile in patients with HER2-negative metastatic urothelial carcinoma.

Dr. Gupta on the Results of the PARADIGM Study in Urothelial Cancer

June 28th 2022

Shilpa Gupta, MD, discusses the results of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Successful Treatment Options Expand to Earlier Lines in RCC and Urothelial Cancer

June 23rd 2022

Tian Zhang, MD, discusses the benefits of multidisciplinary collaboration, how to select the best agents for each patient, and how treatments such as radiation in RCC and bladder-sparing chemoradiation in urothelial cancer fit into the overall treatment paradigms for these diseases.

Dr. Gupta on the Methodologies of the PARADIGM Study in Urothelial Cancer

June 20th 2022

Shilpa Gupta, MD, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Gupta on the Design of the PARADIGM Study in Urothelial Cancer

June 19th 2022

Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Packiam on Safety of Cabazitaxel/Gemcitabine Plus Pembrolizumab in Urothelial Carcinoma

June 15th 2022

Vignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Maintenance Avelumab Maintains Survival Benefit as First-Line Maintenance Across Subgroups in Advanced Urothelial Cancer

June 4th 2022

The addition of maintenance avelumab to best supportive care demonstrated improved outcomes for patients with advanced urothelial carcinoma including those who went on to receive second-line therapy.

TMB Serves as Predictive Biomarker of Toripalimab Efficacy in Urothelial Carcinoma

June 4th 2022

Tumor mutational burden served as a prognostic indicator of the efficacy of toripalimab among Chinese patients with urothelial carcinoma.

Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer

June 4th 2022

Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.

Single-Agent Cabozantinib Stalls as Maintenance Therapy in Advanced Urothelial Cancer

June 4th 2022

Results of the ATLANTIS study do not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer.

Dr. Galsky on Initial Data From the CheckMate 274 Trial in Urothelial Cancer

June 1st 2022

Matthew Galsky, MD, discusses the design and findings of the phase 3 CheckMate 274 trial in urothelial cancer.

Neoadjuvant Enfortumab Vedotin May Be an Option for Cisplatin-Ineligible MIBC

May 28th 2022

Neoadjuvant administration of the antibody drug conjugate enfortumab vedotin-ejfv represents a potential future treatment option for patients with muscle invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Dr. Packiam the Investigation of Cabazitaxel Plus Gemcitabine with Pembrolizumab in Urothelial Carcinoma

May 25th 2022

Vignesh Packiam, MD, discusses the investigation of cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Dr. Galsky on the Rationale of the CheckMate 274 Trial in Urothelial Carcinoma

May 24th 2022

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer.

FDA Approval Sought for N-803 Plus BCG in BCG-Unresponsive NMIBC Carcinoma in Situ

May 23rd 2022

A biologics license application seeking the approval of N-803 in combination with Bacillus Calmette-Guérin in patients with BCG-unresponsive, non–muscle invasive bladder cancer carcinoma in situ with or without Ta or T1 disease has been submitted to the FDA.